

## Associate Directors Meeting MINUTES

<b>MEETING DATE/TIME</b>	March 14 <sup>th</sup> , 2022 / 1:00 – 2:00 pm			
<b>EXECUTIVE OWNER</b>	Eileen White/Anita Kinney			
<b>EXECUTIVE NOTE TAKER</b>	Gina Londino-Greenberg			
<b>ATTENDEES</b>		Present		Present
	David August	X	Edmund Lattime	X
	Adam Berger	X	Zhiyuan Shen	X
	<del>Andrew Evens</del>		Linda Tanzer	X
	Shridar Ganesan	X	Eileen White	X
	Howard Hochster	X	Gina Londino-Greenberg	X
	<del>Yibin Kang</del>		Ioannis Stasinopoulos	X
	<del>Anita Kinney</del>			
	Haejin In	X		

AGENDA TOPICS		
TOPIC	DISCUSSION/CONCLUSION	RECOMMENDATION /ACTION
<b>Urgent Issues (Team)</b>		
<b>New Business (Team)</b>		
<b>Deputy Director's Report (White)</b>	<p>There was discussion about the future of the developing PDX/PDO core, now that H. Sabaawy will be leaving Rutgers Cancer Institute. A technician to work in this new core has not yet been hired. The space and equipment for the new PDX/PDO core are available. S. Ganesan offered to help to look into what can be done in the core until someone is hired. E. Lattime advised that the room being considered to serve as the developing PDX/PDO core may not be usable if the C06 grant application being submitted gets funded, as construction will then occur in the area. There was agreement that it would be necessary to determine which renovations to the space allocated for the developing PDX/PDO core were necessary and which were relevant specifically for H. Sabaawy.</p> <p>The question was raised of whether the AD Meeting should be renamed, such as to "Executive Committee", in order to align more with what other Comprehensive Cancer Centers do. There was uncertainty about whether such a change was necessary.</p>	<p>A. Berger can present at a future AD Meeting or Research Leadership Council Meeting to provide updates and discuss what could be possible for the developing PDX/PDO core.</p> <p>E. White will communicate further with A. Kinney about whether it will be necessary to rename the AD Meeting.</p>
<b>Catchment Area Updates (Kinney)</b>		
<b>Future of Comprehensive Omics in the Shared Resources (Ganesan)</b>	Please see attached presentation. Rutgers New Jersey Medical School Research Genomics Laboratory (R-NJMS-RGL) would benefit from a partnership with Rutgers Cancer Institute by being able to obtain samples and charging for their services. It would be helpful to know about other cancer-relevant services that could be offered by this Genomics core.	<p>S. Ganesan will reach out to R-NJMS-RGL to arrange for a presentation to the faculty to provide further information on the services offered.</p> <p>A. Berger will see what data R-NJMS-RGL has on grant</p>

	<p>The Immune Monitoring Core is providing single-cell isolation for RNA sequencing. Rutgers Cancer Institute does not currently have in-house sequencing services. Several PIs are using the Genomics core at Cold Spring Harbor Laboratory and most use commercial vendors such as Genewiz..</p>	<p>and publications supported by its services, as well as how it is financed and what might be needed from Rutgers Cancer Institute. He will then present the findings at either an AD Meeting or a Research Leadership Council Meeting.</p>
<p><b>Updates from Office of DEI (In)</b></p>	<p>Proposals are being taken from consultants to develop a DEI training program. After getting feedback, it seems that it is better to conduct such a training in a team environment. The training could even be some type of team-building exercise.</p> <p>A visual display is being developed to share a gender diversity inclusion statement on the bathrooms. H. In is working with Social Worker J. Hogan to identify appropriate training programs for staff to accompany the signs going up.</p> <p>Rutgers Cancer Institute will have a booth at the ASCO conference, to help with recruitment of diverse faculty, and will see if a booth can be arranged for the 2023 AACR conference.</p>	
<p><b>Next Meeting</b></p>	<p><b>April 11<sup>th</sup> at 1:00 pm</b></p>	